Close Menu

BioMérieux

The FDA gave the nod to Shenzhen Bioeasy Biotechnology for two lateral flow immunoassays that provide preliminary results in detecting marijuana in urine. 

Roche Diagnostics got the nod for its Elecsys Anti-HAV II test for the detection of total antibodies ­­— IgG and IgM — to the hepatitis A virus.

Clinical applications grew 11 percent driven by 34 percent growth in the molecular biology segment, including a 31 percent spike in FilmArray product sales.

By measuring and analyzing hospital testing operations, the firm anticipates helping its customers implement better antimicrobial stewardship programs.

Included in the 510(k) clearances was one for AMS Diagnostics' Liasys 600 Electrolyte Measurement System for measuring sodium, chloride, and potassium in human serum.

Siemens Healthineers received clearance for its Dimension Exl High-Sensitivity Troponin I Assay used to diagnose acute myocardial infarction.

BioMérieux has increased its stake in Chinese immunoassay developer Hybiome Biomedical Engineering from 54 percent to 67 percent.

In the quarter the firm acquired food and beverage testing firm Invisible Sentinel and partnered with Baxter International to develop acute kidney injury biomarkers.

A display at a booth at ECCMID where antimicrobial resistance was a major theme.

Industry executives said that clinical needs associated with antimicrobial resistance and sepsis are generating more interest in AST technologies.

VALUE-Dx involves six IVD companies and is being heralded by participants as an opportunity for competitors to work together to improve test adoption.

Pages